Campath and CLL
The prescription drug Campath® (alemtuzumab) is licensed to treat a type of leukemia known as B-cell chronic lymphocytic leukemia (B-CLL). It comes as an injection that is given for 12 weeks.
Campath belongs to a group of drugs called monoclonal antibodies, which means it is approved for use alone (as a single agent) to treat people with B-CLL. It may reduce symptoms of leukemia and extend the time a person is able to live without their condition getting worse. Some people may experience a complete disappearance of their leukemia symptoms. However, not everyone will respond to the medication in the same way.
(To learn more about how this drug works to treat B-CLL, click Campath Uses. This article also explains whether it can be given to children and older adults, and lists some off-label uses.)